IL144635A0 - Novel polypeptides involved in immune response - Google Patents

Novel polypeptides involved in immune response

Info

Publication number
IL144635A0
IL144635A0 IL14463500A IL14463500A IL144635A0 IL 144635 A0 IL144635 A0 IL 144635A0 IL 14463500 A IL14463500 A IL 14463500A IL 14463500 A IL14463500 A IL 14463500A IL 144635 A0 IL144635 A0 IL 144635A0
Authority
IL
Israel
Prior art keywords
immune response
novel polypeptides
polypeptides involved
involved
novel
Prior art date
Application number
IL14463500A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL144635A0 publication Critical patent/IL144635A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
IL14463500A 1999-02-03 2000-01-27 Novel polypeptides involved in immune response IL144635A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24444899A 1999-02-03 1999-02-03
US26452799A 1999-03-08 1999-03-08
PCT/US2000/001871 WO2000046240A2 (en) 1999-02-03 2000-01-27 Polypeptides involved in immune response

Publications (1)

Publication Number Publication Date
IL144635A0 true IL144635A0 (en) 2002-05-23

Family

ID=26936541

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14463500A IL144635A0 (en) 1999-02-03 2000-01-27 Novel polypeptides involved in immune response
IL144635A IL144635A (en) 1999-02-03 2001-07-30 Antibody associated with b7rp1 polypeptide due
IL229857A IL229857A0 (en) 1999-02-03 2013-12-08 1rp7b mature polypeptide binding antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL144635A IL144635A (en) 1999-02-03 2001-07-30 Antibody associated with b7rp1 polypeptide due
IL229857A IL229857A0 (en) 1999-02-03 2013-12-08 1rp7b mature polypeptide binding antibody

Country Status (18)

Country Link
US (3) US20080152651A1 (pt)
EP (4) EP2332978B1 (pt)
JP (2) JP5000804B2 (pt)
KR (1) KR20010101987A (pt)
CN (1) CN1309734C (pt)
AU (1) AU773954B2 (pt)
CA (2) CA2640956C (pt)
CY (3) CY1115099T1 (pt)
DK (3) DK1149114T3 (pt)
ES (3) ES2464161T3 (pt)
HK (2) HK1159128A1 (pt)
HU (1) HUP0105337A3 (pt)
IL (3) IL144635A0 (pt)
NZ (3) NZ551331A (pt)
PT (3) PT2332976E (pt)
SI (3) SI2332976T1 (pt)
TW (1) TWI274058B (pt)
WO (1) WO2000046240A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
JP5000804B2 (ja) * 1999-02-03 2012-08-15 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
AU6458400A (en) * 1999-08-11 2001-03-13 Isis Innovation Limited Nucleic acid, polypeptides, assays, therapeutic methods and means
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
EP1900816A3 (en) * 1999-09-21 2008-03-26 Genetics Institute, LLC GL50 molecules and uses therefor
US6521749B1 (en) * 1999-09-21 2003-02-18 Genetics Institute, Inc. GL50 nucleic acids and uses therefor
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4236925B2 (ja) * 2000-11-28 2009-03-11 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
US20040152156A1 (en) * 2001-01-04 2004-08-05 Jeffrey Encinas Regulation of human b7-h2 protein
CA2434690A1 (en) * 2001-01-16 2002-09-06 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
AU2002308267A1 (en) * 2001-01-16 2002-10-03 Bayer Aktiengesellschaft Regulation of human icos v protein
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
WO2005103086A1 (en) 2004-04-23 2005-11-03 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
EP3673919A1 (en) * 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
NO345593B1 (no) * 2005-07-18 2021-05-03 Amgen Inc Humane anti-B7RP1 nøytraliserende antistoffer
AU2011265342B2 (en) * 2005-07-18 2014-12-04 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
AU2013203437A1 (en) * 2005-07-18 2013-05-02 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
CA2630483C (en) 2005-12-08 2015-05-19 Medarex, Inc. Human monoclonal antibodies to o8e
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
IL280738B (en) * 2014-04-16 2022-07-01 Juno Therapeutics Gmbh Methods, kits and device for increasing cell populations
AU2016215175B2 (en) * 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
US10023635B2 (en) 2015-03-23 2018-07-17 Jounce Therapeutics, Inc. Antibodies to ICOS
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
CA2998208A1 (en) 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5521288A (en) * 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
EP0832269A1 (en) 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
EP1017723B1 (de) * 1997-09-23 2007-01-10 Bundesrepublik Deutschland letztvertreten durch Den Direktor des Robert-Koch-Instituts Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP5000804B2 (ja) 1999-02-03 2012-08-15 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) * 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
AU6458400A (en) 1999-08-11 2001-03-13 Isis Innovation Limited Nucleic acid, polypeptides, assays, therapeutic methods and means
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
US6521749B1 (en) 1999-09-21 2003-02-18 Genetics Institute, Inc. GL50 nucleic acids and uses therefor
EP1900816A3 (en) 1999-09-21 2008-03-26 Genetics Institute, LLC GL50 molecules and uses therefor
AU2001245396A1 (en) 2000-03-02 2001-09-12 Mayo Foundation For Medical Education And Research Hb7-h2, a novel co-stimulatory molecule
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US7030255B2 (en) * 2004-03-09 2006-04-18 Lyondell Chemical Technology, L.P. Oxidation process with in-situ H202 generation and polymer-encapsulated catalysts therefor
NO345593B1 (no) * 2005-07-18 2021-05-03 Amgen Inc Humane anti-B7RP1 nøytraliserende antistoffer
US8615703B2 (en) 2010-06-04 2013-12-24 Micron Technology, Inc. Advanced bitwise operations and apparatus in a multi-level system with nonvolatile memory

Also Published As

Publication number Publication date
NZ551331A (en) 2008-08-29
EP2332978B1 (en) 2014-04-02
HUP0105337A2 (hu) 2002-04-29
US8470317B2 (en) 2013-06-25
CA2362126A1 (en) 2000-08-10
US20080152651A1 (en) 2008-06-26
CA2640956A1 (en) 2000-08-10
JP5658695B2 (ja) 2015-01-28
CY1115102T1 (el) 2016-12-14
EP1149114A2 (en) 2001-10-31
JP5000804B2 (ja) 2012-08-15
DK2332978T3 (da) 2014-06-23
DK1149114T3 (da) 2014-06-23
JP2012110333A (ja) 2012-06-14
TWI274058B (en) 2007-02-21
DK2332976T3 (da) 2014-06-23
ES2464165T3 (es) 2014-05-30
ES2464161T3 (es) 2014-05-30
CA2362126C (en) 2017-01-17
CA2640956C (en) 2012-07-03
JP2002539770A (ja) 2002-11-26
AU2859200A (en) 2000-08-25
HK1159127A1 (en) 2012-07-27
AU773954B2 (en) 2004-06-10
WO2000046240A3 (en) 2000-12-21
NZ583002A (en) 2011-12-22
EP2332976B1 (en) 2014-04-02
EP2796465A1 (en) 2014-10-29
KR20010101987A (ko) 2001-11-15
PT2332976E (pt) 2014-05-23
ES2464156T3 (es) 2014-05-30
IL229857A0 (en) 2014-01-30
CN1346370A (zh) 2002-04-24
PT2332978E (pt) 2014-05-23
EP1149114B1 (en) 2014-04-02
CN1309734C (zh) 2007-04-11
EP2332976A1 (en) 2011-06-15
SI1149114T1 (sl) 2014-08-29
PT1149114E (pt) 2014-05-22
SI2332976T1 (sl) 2014-08-29
US20140256652A1 (en) 2014-09-11
CY1115101T1 (el) 2016-12-14
IL144635A (en) 2014-05-28
EP2332978A1 (en) 2011-06-15
NZ513349A (en) 2004-03-26
US20090208504A1 (en) 2009-08-20
HUP0105337A3 (en) 2011-01-28
CY1115099T1 (el) 2016-12-14
WO2000046240A2 (en) 2000-08-10
HK1159128A1 (en) 2012-07-27
SI2332978T1 (sl) 2014-08-29

Similar Documents

Publication Publication Date Title
HK1159127A1 (en) Novel polypeptides involved in immune response
GB9923177D0 (en) Novel polypeptide
GB9921125D0 (en) Proteins
AU1796902A (en) Novel polypeptides involved in immune response
DE60015325D1 (en) Offset-kompensation in analog-digital wandlern
AU5205899A (en) Enhancing immune response in animals
GB9923889D0 (en) Novel polypeptide
EP1241257A4 (en) TACHYKININ-SIMILAR POLYPEPTIDES AND ITS APPLICATION
EP1162269A4 (en) NEW POLYPEPTIDE
GB9903430D0 (en) Novel proteins
GB9917165D0 (en) Polypeptides polynuclcotides and uses thereof
GB9807062D0 (en) Immune response
GB9920000D0 (en) Polypeptides
GB9923890D0 (en) Novel polypeptide
GB0112374D0 (en) Novel protein
EP1146053A4 (en) PROTEIN MEG-4
GB9925115D0 (en) Novel polypeptide
GB9923888D0 (en) Novel polypeptide
GB9924960D0 (en) Novel polypeptide
GB9924956D0 (en) Novel polypeptide
GB9906307D0 (en) Novel polypeptides
GB9918680D0 (en) Polypeptide
EP1152059A4 (en) NOVEL CYTOKINE RECEPTOR TYPE PROTEIN
GB9923892D0 (en) Novel polypeptide
GB9924953D0 (en) Novel polypeptide